Top Big Pharma Stocks: Our 5 Best Picks for October 2026
A five-stock big pharma countdown spans vaccines, oncology, immunology and MedTech, featuring Amgen, Pfizer and Johnson & Johnson among diversified names.
Big pharma is regaining investor attention as healthcare offers a combination of defensive cash flows, established commercial franchises and renewed growth optionality. The sector is less dependent on the macroeconomic cycle than many industries, yet its largest companies are still positioned to benefit when new therapies move from research laboratories into broad clinical use. That combination matters in October 2026, as investors weigh valuation discipline against the possibility of a stronger pharmaceutical innovation cycle.
Several forces are reinforcing the theme. Clearer U.S. drug-pricing and tariff frameworks could reduce uncertainty, while resilient research and development spending continues to support the pipeline. The approaching patent cliff is also pushing large drugmakers toward acquisitions and late-stage pipeline purchases. Obesity and GLP-1 therapies, oncology, immunology, vaccines and the tools and CDMO ecosystem are among the most important areas to understand. May 2026 reporting that biotech dealmaking was on pace for a strong year underscored how central M&A has become to revenue replacement.
The five companies below represent different ways to access big pharma, from diversified medicines and vaccines to biotechnology-led portfolios and medical technology. The countdown proceeds from #5 to #1, with exposure to the theme considered first and business fundamentals used to separate otherwise comparable companies. The result is a mix of steadier franchises, turnaround situations and higher-growth therapeutic platforms.
How we ranked the stocks
The screen covers U.S.-listed companies with market capitalizations above $500 million and meaningful exposure to big pharma. We ranked candidates first by the depth of that exposure: the breadth of their drug discovery, development, manufacturing and commercialization activities, plus participation in major therapeutic categories. Business fundamentals then provided the tie-breaker, including revenue and earnings growth, profitability, valuation, earnings execution, analyst sentiment and our composite quality grade. This is a countdown, so the highest-ranked pick is reserved for #1 at the end.
What they do. The company discovers, develops, manufactures and delivers human therapeutics worldwide. Its portfolio spans immunology products such as Enbrel and Otezla, bone-health medicines including Prolia, XGEVA and EVENITY, cardiovascular therapy Repatha, and oncology products such as BLINCYTO, Vectibix and KYPROLIS. That breadth gives Amgen a diversified commercial base supported by physician, hospital, pharmacy and wholesale distribution relationships.
Why it fits. Amgen is a direct big-pharma exposure through its combination of biologics, specialty medicines and global manufacturing capabilities. Its presence in immunology, oncology, cardiovascular disease and osteoporosis touches several of the theme's strongest sub-segments, while collaborations involving TEZSPIRE, EVENITY, rocatinlimab and oncology products extend the company's pipeline reach.
Numbers that matter. Revenue growth was 9.5% year over year and earnings growth was 64.9%, giving Amgen one of the stronger reported growth profiles in this group. Gross margin was 71.9%, operating margin was 35.55% and net margin was 22.95%, while ROE was 91.47%. The core valuation data show a trailing P/E of 28.064 and forward P/E of 18.1488; comparing the $244.3 billion market cap with $38.094999552 billion of revenue implies roughly 6.4 times sales.
Recent momentum. Amgen has beaten earnings estimates in 7 of the last 7 reported quarters. In the latest completed quarter, EPS was $6.29 versus a $5.60 estimate, a 12.3% surprise. Analysts are more cautious than the earnings record: the consensus breakdown is 4 Buy, 17 Hold and 2 Sell, producing a Hold consensus and a $397.3231 average target.
Market cap: $167.9B · Quality grade: B · Analyst consensus: Hold (avg target $29.26)
What they do. The company discovers, develops, manufactures, markets and distributes biopharmaceutical products across the United States and international markets. Its portfolio includes Eliquis, Nurtec, the Prevnar vaccine family, Abrysvo, Paxlovid, Vyndaqel, a broad inflammation and immunology franchise, and oncology products such as Ibrance, Padcev, Adcetris and Elrexfio. Pfizer also operates in biosimilars, sterile injectables and Pfizer Ignite, giving it multiple commercial channels.
Why it fits. Pfizer offers unusually broad exposure to the big-pharma ecosystem, with vaccines, internal medicine, rare disease, immunology, oncology and hospital products under one platform. Its collaborations with Bristol-Myers Squibb, Astellas, Merck KGaA and BioNTech add external innovation to an internal portfolio, an important feature as large drugmakers prepare for patent-related revenue pressure.
Numbers that matter. Pfizer's revenue growth was 2.6% year over year, while earnings growth was negative 10.1%, showing a slower fundamental trajectory than several peers. Gross margin was 74.7%, operating margin was 27.88% and net margin was 6.8%; ROE and ROA were 5.01% and 5.78%, respectively. The trailing P/E was 38.75 versus a forward P/E of 10.2354, and the $167.9 billion market cap against $63.695998976 billion of revenue implies roughly 2.6 times sales.
Recent momentum. Pfizer has beaten estimates in 7 of its last 7 reported quarters. The latest completed quarter produced EPS of $0.77 against an estimate of $0.68, a 13.2% surprise. The analyst breakdown is much more restrained than that streak: 1 Buy, 17 Holds and 1 Sell, for a Hold consensus and a $29.2596 average target.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
What they do. Johnson & Johnson operates through Innovative Medicine and MedTech. Innovative Medicine covers oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolic conditions, while MedTech supplies products for surgery, orthopedics, cardiovascular care, vision, robotics and digital technologies. That combination creates a broader healthcare business model than a pure-play drugmaker.
Why it fits. J&J belongs in a big-pharma ranking because its Innovative Medicine segment provides exposure to core therapeutic categories, while MedTech adds a separate source of healthcare demand. Oncology and immunology are particularly relevant to the current industry pipeline, and the MedTech platform can provide diversification as drug pricing, patents and clinical outcomes shape pharmaceutical returns.
Numbers that matter. Revenue grew 5.9% year over year, but reported earnings growth was negative 95.9%, making the earnings comparison a key issue for investors to monitor. Gross margin was 67.8%, operating margin was 25.74% and net margin was 16.2%, with ROE of 20.02% and ROA of 8.46%. The trailing P/E was 41.129 and forward P/E was 22.6757; the $652.5 billion market cap relative to $99.334995968 billion of revenue implies approximately 6.6 times sales.
Recent momentum. J&J has beaten estimates in 7 of the last 8 reported quarters, including the latest quarter, when EPS of $2.59 exceeded the $2.53 estimate by 2.4%. Analysts show 5 Buys and 6 Holds, with no Sell count reported, resulting in a Buy consensus and a $279.4091 average target. The recent earnings record is steady, although the sharp reported earnings decline means the quality of that growth requires continued attention.
Pick #2Premium members only
Premium members see this pick's full breakdown — investment thesis, key financial metrics, recent earnings execution, and analyst consensus.
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
This monthly screen begins with U.S.-listed companies in the big-pharma universe and excludes businesses below $500 million in market capitalization. Ranking emphasizes depth of exposure to drug discovery, development, manufacturing and commercialization, as well as participation in major therapeutic categories such as oncology, immunology, vaccines and specialty medicine. Business fundamentals then determine placement, using revenue and earnings growth, margins, return metrics, valuation, earnings surprises, analyst consensus and our composite quality grade. The list is presented as a countdown from #5 to #1 and is refreshed monthly as the underlying data change.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
